From: FGFR1 is amplified during the progression of in situto invasive breast carcinoma
 |  | Subtype | |||||
---|---|---|---|---|---|---|---|
Histologic stage | Gene | Luminal A | Luminal B | HER2-positive | Basal-like | TNNB | Pvaluea |
Invasive carcinoma | C-MYC | 13/208 (6.3)*,** | 15/103 (14.6)** | 7/42 (16.7) | 14/55 (25.5)* | 5/19 (26.3) | < 0.001 |
 | CCND1 | 19/205 (9.3)†| 37/103 (35.9)†,‡,§ | 4/42 (9.5)‡ | 0/55 (0)†| 1/18 (5.3)§ | < 0.001 |
 | FGFR1 | 21/202 (10.4)¶ | 21/100 (21.0)¶,††,‡‡ | 3/42 (7.1)††| 7/55 (12.7) | 0/18 (0)‡‡ | 0.025 |
Pure DCIS | C-MYC | 6/98 (6.1) | 4/24 (16.7) | 6/34 (17.6) | 1/9 (11.1) | 0/8 (0) | 0.198 |
 | CCND1 | 11/99 (11.1) | 6/24 (25.0) | 4/35 (11.4) | 0/9 (0) | 1/8 (12.5) | 0.298 |
 | FGFR1 | 5/95 (5.3) | 4/23 (17.4) | 1/33 (3.0) | 0/9 (0) | 0/8 (0) | 0.134 |